Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
551 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02737072 | A Study of LY2510924 and Durvalumab in Participants With Solid Tumors | terminated | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 0 | Aug 12, 2019 | clinicaltrials |
| NCT02783599 | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | completed | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 12, 2019 | clinicaltrials |
| NCT01158404 |
| Notch Inhibitor in Advanced Cancer |
| completed |
| Phase 1 |
| 35 |
| Eli Lilly and CompanyINDUSTRY |
| 1 |
| Aug 9, 2019 |
| clinicaltrials |
| NCT01111604 | A Study of Ramucirumab or Icrucumab in Colorectal Cancer | completed | Phase 2 | 158 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 6, 2019 | clinicaltrials |
| NCT02734160 | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 | 37 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 5, 2019 | clinicaltrials |
| NCT02778126 | A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer | completed | Phase 1 | 6 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 1, 2019 | clinicaltrials |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 110 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01137006 | An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma | completed | Phase 1 | 27 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01288989 | A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01648764 | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | completed | Phase 1 | 73 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 17, 2019 | clinicaltrials |
| NCT01212107 | A Phase 1 Study of LY2874455 in Participants With Advanced Cancer | completed | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 12, 2019 | clinicaltrials |
| NCT01214655 | A Study for Patients With Acute Leukemia | terminated | Phase 1 | 33 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2019 | clinicaltrials |
| NCT00509821 | Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 5, 2019 | clinicaltrials |
| NCT00642018 | A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer | completed | Phase 2 | 154 | Eli Lilly and CompanyINDUSTRY | 4 | Apr 3, 2019 | clinicaltrials |
| NCT01524224 | A Dose-Escalation Study in Participants With Advanced Cancer | completed | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 1, 2019 | clinicaltrials |
| NCT01556438 | Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma | completed | Phase 1 | 16 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01209832 | A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients | terminated | Phase 1 | 11 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 18, 2019 | clinicaltrials |
| NCT01215916 | A Phase 1 Study in Patients With Solid Tumors | completed | Phase 1 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 15, 2019 | clinicaltrials |
| NCT02745769 | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | completed | Phase 1 | 23 | Eli Lilly and CompanyINDUSTRY | 3 | Mar 5, 2019 | clinicaltrials |
| NCT01341457 | A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors | completed | Phase 1 | 17 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01007032 | A Study of IMC-A12 in Advanced Solid Tumors | completed | Phase 1 | 21 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT01634555 | A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI | completed | Phase 2 | 29 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01287520 | A Study of LY2090314 in Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 41 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 25, 2019 | clinicaltrials |
| NCT01119456 | A Study of IMC-RON8 in Advanced Solid Tumors | completed | Phase 1 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02555644 | A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer | completed | Phase 1 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 15, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT01394003 | A Study of LY2584702 in Participants With Advanced Cancer | terminated | Phase 1 | 34 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01646203 | A Study of IMC-TR1 in Participants With Advanced Solid Tumors | completed | Phase 1 | 14 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01632306 | A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00718159 | Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia | completed | Phase 1 | 23 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT00918203 | A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 137 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01258348 | A Phase 1b Trial in Patients With Renal Cell Cancer | completed | Phase 1 | 21 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01284335 | A Safety Study in Participants With Advanced Solid Tumors | terminated | Phase 1 | 234 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT00785538 | A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available | completed | Phase 1 | 24 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01296568 | C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 3 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT02117648 | A Study of LY2835219 in Participants With Cancer | completed | Phase 1 | 26 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01214668 | Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors | completed | Phase 1 | 31 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 26 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 15 | Dec 14, 2018 | clinicaltrials |
| NCT02860780 | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 14, 2018 | clinicaltrials |
| NCT02069041 | A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer | completed | Phase 1 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT01214603 | A Study in Participants With Acute Leukemia | completed | Phase 2 | 20 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00475644 | A Study of Enzastaurin in Participants With Follicular Lymphoma | completed | Phase 2 | 66 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 5, 2018 | clinicaltrials |
| NCT01358968 | A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine | completed | Phase 1 | 20 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00363766 | Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 19, 2018 | clinicaltrials |
| NCT00415636 | Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer | completed | Phase 1 | 31 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT01185548 | A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma(JZAR) | terminated | Phase 1 | 4 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT01340976 | A Phase 1 Study of LY2787106 in Cancer and Anemia | completed | Phase 1 | 33 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00332202 | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | completed | Phase 3 | 758 | Eli Lilly and CompanyINDUSTRY | 25 | Sep 10, 2018 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials